ASX Code: MEM



ASX Release 19 January 2024

Change of venue for General Meeting of shareholders

Dear Shareholders,

The Memphasys Limited General Meeting (GM) is to be held on Wednesday, 14th February 2024, however due to unforeseen circumstances the venue address for holding the meeting has been changed.

Initially scheduled to take place at 30 Richmond Road, Homebush West, NSW 2140, we have had to make the decision to relocate the GM to a new venue. The new location for the Memphasys Limited General Meeting is as follows:

New Venue: The Dunn Room; Level 14, 333 Collins Street, Melbourne Victoria

Date and Time remain unchanged: Wednesday 14 February 2024 10:00am (AEDT)

Thank you for your continued support of Memphasys Limited. We look forward to your participation in the General Meeting and appreciate your understanding regarding this change of venue.

ENDS

Approved by the Board of Memphasys Limited

For further information, please contact:Andrew MetcalfeDr David AliAndrew MetcalfeInterim Managing Director / Chief Executive OfficerCompany SecretaryMemphasys LimitedMemphasys LimitedTel: +61 2 8415 7300Tel: +61 412 125 090E: david.ali@memphasys.comE: andrew@accosec.com

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, *in vitro* diagnostics, and new proprietary media. The Company's patented bio-separation technology, utilised by the Company's most advanced product, the Felix[™] System device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix[™] System is a registered trademark of Memphasys Limited. All rights reserved.